Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 2,524 | 2,630 | 1,975 | 2,382 | 2,273 |
| Cost of Goods | 2,215 | 2,304 | 1,686 | 2,017 | 2,007 |
| Gross Profit | 309 | 327 | 289 | 365 | 267 |
| Operating Expenses | 940 | 1,968 | 715 | 461 | 15 |
| Operating Income | -416 | -1,338 | 259 | -79 | 258 |
| Interest Expense | 34 | 35 | 50 | 29 | 0 |
| Other Income | 28 | 29 | 45 | 24 | -4 |
| Pre-tax Income | -422 | -1,344 | 255 | -84 | 254 |
| Income Tax | -74 | 2 | 56 | 20 | -55 |
| Net Income Continuous | -348 | -1,345 | 199 | -104 | 309 |
| Net Income | $-348 | $-1,345 | $199 | $-104 | $309 |
| EPS Basic Total Ops | -0.26 | -0.75 | 0.11 | -0.01 | 1.88 |
| EPS Basic Continuous Ops | -0.26 | -0.75 | 0.11 | -0.01 | 1.62 |
| EPS Diluted Total Ops | -0.26 | -0.75 | 0.11 | -0.01 | 1.88 |
| EPS Diluted Continuous Ops | -0.26 | -0.75 | 0.11 | -0.01 | 1.62 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.20 | 0.10 | N/A | N/A |
| EBITDA(a) | $-339 | $-1,254 | $340 | $-21 | $287 |